Valeant Looks Past Cephalon For Acquisitions

Valeant Pharmaceuticals, which dropped a $5.7 billion offer for Cephalon earlier this week, will actively pursue other large takeover deals, its chief executive said on Tuesday.

CEO Michael Pearson said the Canadian drug company is looking at acquisitions of all sizes and that Valeant had the financial firepower to do a deal bigger than that of Cephalon.

"We are in active discussions in our different geographies," Pearson told Reuters in an interview.

"Quite frankly, we were in discussions even when this Cephalon thing was going on. There was no guarantee it was going to happen and we understood that," he added.

On Monday, Valeant pulled out of the race to buy Cephalon after Israel's Teva Pharmaceutical Industries agreed to buy the U.S.-based drugmaker for $81.50 a share, topping Valeant's $73-a-share bid.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.